Split First Dose Administration of Intravenous Daratumumab for the Treatment of Multiple Myeloma (MM) : Clinical and Population Pharmacokinetic Analyses
-
Xu, X. S. (Janssen Research & Development. LLC)
;
Moreau, Philippe (CHU de Nantes) ;
Usmani, S. Z. (Levine Cancer Institute/Atrium Health) ;
Lonial, S. (Winship Cancer Institute. Emory University) ;
Jakubowiak, A. (University of Chicago Medical Center) ;
Oriol, Albert (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Krishnan, A. (City of Hope) ;
Bladé Creixenti, Juan (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Luo, M. (Janssen Research & Development. LLC) ;
Sun, Y. N. (Janssen Research & Development. LLC) ;
Zhou, H. (Janssen Research & Development. LLC) ;
Nnane, I. (Janssen Research & Development. LLC) ;
Deraedt, W. (Janssen Research & Development) ;
Qi, M. (Janssen Research & Development. LLC) ;
Ukropec, J. (Janssen Scientific Affairs. LLC) ;
Clemens, P. L. (Janssen Research & Development. LLC) ;
Universitat Autònoma de Barcelona
visitant ::
identificació
Subscriure's to this discussion. You will then receive all new comments by email.
